Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.10, read 2026-11-01
Ethical does not pass the values gate
Price21.69 USD
Fair value30.62
Ethical score70.0/100
Value readUndervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-10-23Read Accumulation20.68+4.9% to today ✓Markdown gives way to Accumulation after a 7% rise in 5 weeks
2026-09-17Read Markdown19.29+12.4% to today Markup gives way to Markdown after a 7% rise in 11 weeks
2026-07-02Read Markup18.02+20.4% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Wolverine World Wide, Inc. holds its Accumulation at $21.69. The statistical read favours the sellers, held for 29 days.
As held on the ledger · 2026-11-05
Phase
Accumulation
Quantitative state
The statistical read favours the sellers, held for 29 days
Price at the screen
$21.69
Valuation
16.81 trailing · 11.73 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.67
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
44.58%
Below 33%
Interest-bearing debt is 44.6% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
21.55%
Below 49%
Money owed to the company is 21.6% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Wolverine World Wide,'s business is in a permissible area, but its interest-bearing debt is about 45% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when WWW's ethical verdict changes
Today WWW does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 5 Nov 2026: it trades at roughly a 29% discount to our $30.62 fair value, 6.80% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 29.2% discount to the base estimate.
Where our models see it going: fair-value estimate $30.62, with a range of $30.51 to $43.38, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Shoe sales chase consumer cycles that rarely last
Wolverine makes boots and trainers that sell when wallets are open and fade when belts tighten. Revenue is growing 11 percent and the shares sit on a forward multiple of 10.5 times, yet the business sits squarely inside consumer cyclical demand that peaks and troughs with jobs and confidence. The 40 percent gap to our fair value looks tempting on paper, but the low multiple is flashing a warning rather than a bargain.
ROE of 29 percent shows the firm can earn, yet margins remain thin at 5 percent and the sector has a habit of turning those returns quickly when spending slows. Ten analysts still say buy with a $20 target, but the cyclical value trap is exactly why the opportunity rating stays at none despite the ethical screen clearing.
Currency moves, fashion shifts and inventory swings add further lumps that a simple earnings multiple does not capture. The numbers do not scream broken company, they simply fail to clear the bar for a cyclical name at this point in the spending cycle.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
WWW trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-06Accumulation$21.69-7.7%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 7.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 13% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 7%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (10 analysts) rates it buy, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-05Accumulation$23.50+15.4%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 15.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 13% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 7%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (10 analysts) rates it buy, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Accumulation$20.36-1.5%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 13% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 7%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (10 analysts) rates it buy, with a mean price target of $22.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 9.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 7%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (10 analysts) rates it buy, with a mean price target of $22.
2026-10-16Markdown$18.83-0.5%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 7%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (10 analysts) rates it buy, with a mean price target of $22.
2026-10-02Markdown$18.93-1.9%Entry 6
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 7%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (10 analysts) rates it buy, with a mean price target of $22.
2026-09-17Markdown · changed$19.29+6.8%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 6.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 7%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (10 analysts) rates it buy, with a mean price target of $22.
2026-08-18Markup$18.06+0.2%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 7%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (10 analysts) rates it buy, with a mean price target of $22.
2026-07-18Markup$18.02+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 7%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (10 analysts) rates it buy, with a mean price target of $22.
2026-07-03Markup$18.02+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
